BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9337685)

  • 21. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amifostine for protection from antineoplastic drug toxicity.
    Foster-Nora JA; Siden R
    Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
    Shaw LM; Bonner HS; Brown DQ
    Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
    Bonner HS; Shaw LM
    J Clin Pharmacol; 2002 Feb; 42(2):166-74. PubMed ID: 11831539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
    Santini V
    Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a method for measuring the radioprotective metabolite WR-1065 in plasma using chemical derivatization combined with UHPLC-MS/MS.
    Simon ES; Reyna D; Lister RJ; Harteg C; Lipka E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Mar; 1080():82-89. PubMed ID: 29482122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of WR-2721 and carboplatin.
    Budd GT; Ganapathi R; Bauer L; Murthy S; Adelstein D; Weick J; Gibson V; McLain D; Sergi J; Bukowski RM
    Eur J Cancer; 1993; 29A(8):1122-7. PubMed ID: 8390844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
    Fulda S; Oster W; Berthold F
    Anticancer Drugs; 1997 Jan; 8(1):34-41. PubMed ID: 9147609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraduodenal administration of ethiofos (WR-2721): dose proportionality study in the rhesus monkey.
    Geary RS; Swynnerton NF; Miller MA; Mangold DJ; Ludden T
    Res Commun Chem Pathol Pharmacol; 1989 Aug; 65(2):147-59. PubMed ID: 2555852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility study of the pharmacology of local application of amifostine (WR-2721) to the buccal mucosa in guinea pigs.
    Li C; Wang S; Huang T; Chen N; Ou M
    Pharmacology; 2013; 91(5-6):281-6. PubMed ID: 23736649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action.
    Grdina DJ; Shigematsu N; Dale P; Newton GL; Aguilera JA; Fahey RC
    Carcinogenesis; 1995 Apr; 16(4):767-74. PubMed ID: 7728953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
    Merlin JL; Marchal S; Ramacci C; Berlion M; Poullain MG
    Anticancer Drugs; 2002 Feb; 13(2):141-7. PubMed ID: 11901306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
    Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites.
    Swynnerton NF; Huelle BK; Mangold DJ; Ludden TM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1495-9. PubMed ID: 3019967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
    McKibbin T; Panetta JC; Fouladi M; Gajjar A; Bai F; Okcu MF; Stewart CF
    Clin Cancer Res; 2010 Feb; 16(3):1049-57. PubMed ID: 20103669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha.
    Murley JS; Kataoka Y; Baker KL; Diamond AM; Morgan WF; Grdina DJ
    Radiat Res; 2007 Apr; 167(4):465-74. PubMed ID: 17388698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
    Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
    Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human pharmacokinetics of WR-2721.
    Shaw LM; Turrisi AT; Glover DJ; Bonner HS; Norfleet AL; Weiler C; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1501-4. PubMed ID: 3019968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.